NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03731260,"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis",https://clinicaltrials.gov/study/NCT03731260,,ACTIVE_NOT_RECRUITING,"This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.",NO,Indolent Systemic Mastocytosis,DRUG: Avapritinib|DRUG: Placebo,"Part 1: Recommended Phase 2 dose (RP2D) in patients with ISM, 9 months|Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) as compared to placebo, 0 - 110 points (higher value represents worse symptom outcomes), 6 months|Part 3: Number of Participants with Adverse Events, Up to 5 years","Part 2: Proportion of patients with a ≥50% reduction in serum tryptase, 6 months|Part 2: Proportion of patients with a ≥50% reduction in peripheral blood V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) allele fraction or undetectable for patients with detectable mutation at Baseline, 6 months|Part 2: Proportion of patients with ≥50% reduction in ISM-SAF TSS, 6 months|Part 2: Proportion of patients with ≥30% reduction in ISM-SAF TSS, 6 months|Part 2: Proportion of patients with a ≥50% reduction in bone marrow mast cells or no aggregates for patients with aggregates at Baseline, 6 months|Parts 1, 2, and 3: Change in serum tryptase, Up to 5 years|Parts 1, 2, and 3: Change in KIT D816V allele burden in blood, Up to 5 years|Parts 1, 2, and 3: Change in bone marrow mast cells, Up to 5 years|Parts 1, 2, and 3: Change in best supportive care (BSC) concomitant medication usage, Up to 5 years|Parts 1, 2, and 3: Change from Baseline in ISM-SAF Score, Up to 5 years|Parts 1, 2, and 3: Change in Mastocytosis Quality of Life Questionnaire (MC-QoL), Up to 5 years|Parts 1, 2, and 3: Change in Patient's Global Impression of Symptom Severity (PGIS), Up to 5 years|Parts 1, 2, and 3: Change in 12-item Short Form Health Survey (SF-12), 0 - 100 points (higher value represents better symptom outcomes), Up to 5 years|Parts 1, 2, and 3: Change in Patients' Global Impression of Change (PGIC), 1 - 7 (higher value represents worse symptom outcomes), Up to 5 years|Parts 1, 2, and 3: Change in EuroQuol 5 Dimensions 5 Levels (EQ 5D-5L), 0 - 100 (higher value represents better symptom outcomes), Up to 5 years|Parts 1, 2, and 3: Safety of avapritinib as assessed by number of adverse events, CTCAE version 5.0, Up to 5 years",,Blueprint Medicines Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE2,251,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",BLU-285-2203|2018-000588-99,2019-04-16,2027-06-23,2028-01-31,2018-11-06,,2024-08-07,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Kansas Hospital, Kansas City, Kansas, 66160, United States|Brigham & Women's Hospital, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Michigan Medicine, University of Michigan, Ann Arbor, Michigan, 48106, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Duke University Health System (DUHS), Durham, North Carolina, 27710, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, 23298, United States|University Hospital Antwerp, Edegem, 2650, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter, Odense, DK-5000, Denmark|Hôpital de la Timone, Service de dermatologie, Marseille, 13385, France|Hôpital Pitié-Salpêtrière, Service de Dermatologie, Paris, 75013, France|CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée, Toulouse, 31059, France|Uniklinik RWTH Aachen, Aachen, 52074, Germany|Charité Universitätsmedizin Berlin, Berlin, 10117, Germany|University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, 20246, Germany|Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie, Lübeck, 23538, Germany|Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center, Mainz, 55131, Germany|Universitätsmedizin Mannheim, III. Medizinische Klinik, Mannheim, 68167, Germany|Klinikum rechts der Isar, Technische Universität München, Munich, 80802, Germany|A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia, Bologna, 40138, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia, Milan, 20122, Italy|A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno, Salerno, 84131, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, 37126, Italy|University Medical Center Groningen (UMCG), Groningen, 9713 GZ, Netherlands|Erasmus Medical Center, Rotterdam, 3015 GD, Netherlands|Oslo Universitetssykehus, Rikshospitalet, Department of Hematology, Oslo, 0372, Norway|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo, Toledo, 45071, Spain|Karolinska University Hospital, Hematologimottagningen R51, Stockholm, 141 86, Sweden|Akademiska sjukhuset, Hematologmottagningen/101A, Uppsala, 751 85, Sweden|University Hospital Basel, Basel, 4031, Switzerland|NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Glasgow, G12 OXL, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, SE1 9RT, United Kingdom|Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, CH63 4JY, United Kingdom",
